CI
CASC

Cowen Inc’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Cowen Inc’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,033
Closed -$108K – 301
2016
Q2 		$108K Hold
19,033
– – 0.01% 195
2016
Q1 		$145K Hold
19,033
– – 0.01% 227
2015
Q4 		$254K Buy
19,033
+13,333
+234% +$230K 0.02% 242
2015
Q3 		$94K Hold
5,700
– – 0.01% 232
2015
Q2 		$128K Sell
5,700
-10,967
-66% -$173K 0.01% 403
2015
Q1 		$163K Hold
16,667
– – 0.01% 357
2014
Q4 		$190K Sell
16,667
-166
-1% -$1.8K 0.02% 181
2014
Q3 		$194K Buy
+16,833
New +$257K 0.02% 261
2014
Q1 		– Sell
-58,333
Closed -$616K – 262
2013
Q4 		$616K Buy
58,333
+25,000
+75% +$279K 0.1% 157
2013
Q3 		$412K Buy
33,333
+5,833
+21% +$61.4K 0.06% 157
2013
Q2 		$259K Buy
+27,500
New +$353K 0.03% 175

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cowen Inc's CASC Position: Q3 2016 in Review

Cowen Inc sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2016, closing a stake of 19,033 shares — an estimated $108K sold.

Cowen Inc first reported a position in CASC in Q2 2013 and held it in 11 quarters. The position peaked at $616K in Q4 2013. 76 funds tracked by Wall St. Rank hold CASC as of Q3 2016.

  • Cowen Inc reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Cowen Inc sold 19,033 Cascadian Therapeutics, Inc. shares in Q3 2016, an estimated $108K.
  • Cowen Inc first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • Cowen Inc's Cascadian Therapeutics, Inc. position peaked at $616K in Q4 2013.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2016.

Based on Cowen Inc's 13F filing for Q3 2016, filed 14 Nov 2016.